Julia MV
LightNews LightNews
julialmv.bsky.social
Julia MV
@julialmv.bsky.social
2K followers 71 following 190 posts
Long COVID patient-researcher
@ Scripps Research & Patient-Led Research Collaborative
Posts Replies Media Videos
Pinned
julialmv.bsky.social
Julia MV @julialmv.bsky.social · 11d
The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is now open for enrollment for people with Long COVID in all states but Hawaii (due to concerns about maintaining temperature control in shipping), DC, and PR:
longcovid.scripps.edu/locitt-t/?ut...
Reposted by Julia MV
chloedecanson.bsky.social
Many Long COVID trials have reported negative results in 2024 and 2025. In our Comment for @thelancetinfdis.bsky.social we argue that inadequate outcome measures might have played a role. (1/12)
THE LANCET Infectious Diseases COMMENT • Online first, November 07, 2025 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease Lara Goxhaj • Lisa McCorkell • Femke van Rhijn-Brouwer . Letícia Soares . Julia Moore Vogel . Chloé de Canson
November 8, 2025 at 12:08 AM
Reposted by Julia MV
heatherhogan.bsky.social
I really do think The Sick Times is doing some of the most important journalism of our generation. And I can tell you firsthand that Miles and Betsy are the real deal. They care so, so much about getting it right. They’re incredible humans in addition to being such good journalists.
thesicktimes.org The Sick Times @thesicktimes.org · 3d
Our #LongCOVID journalism requires reader support — with your help, we can prepare our non-profit newsroom for whatever 2026 brings.

Will you donate today and help us keep this vital work going? the-sick-times.fundjournalism.org/donate/
White text on a purple background reads, "Help us keep holding RFK Jr. accountable. Donate today. The Sick Times + NewsMatch." White text on a purple background reads, On September 18, Health Secretary Robert F. Kennedy Jr. convened a roundtable of top Long COVID experts and government officials. Announced less than 24 hours earlier, the event flew under the radar for most news outlets; even those that focus on science and health were too busy with the CDC vaccine advisory committee meeting that happened on the same day. But at The Sick Times, we dropped all of our other commitments to cover that roundtable." White text on a purple background reads, "And that’s just one example of our work serving the Long COVID community. In the last two years, we have also: Sent 100 issues of our weekly newsletter, including COVID-19 trends, research updates, upcoming community events, and more; Covered key scientific meetings, such as this year’s Keystone Symposia conference, multiple PolyBio symposia, and RECOVER-Treating Long COVID workshops. Been cited, interviewed, and republished by dozens of other news publications; Logged 12 million impressions across social media, spreading Long COVID news to wider audiences." Purple background with white text reads: New donations (followed by a thermometer reaching $60K). New monthly supporters (followed by a thermometer reaching 200). Until December 31, NewsMatch and the Philanthropic Access Partner Fund will match new donations from our readers, up to $1,000 a person! At the bottom is a graphic showing how financial impact is doubled.
November 7, 2025 at 8:50 PM
Reposted by Julia MV
erictopol.bsky.social
Participants are now enrolling in our #longCovid randomized, controlled trial of tirzepatide. The largest trial to test a treatment for this condition. Home-based—no sites. In today's @sandiegouniontribune.com
www.sandiegouniontribune.com/2025/11/01/c...
November 1, 2025 at 2:16 PM
julialmv.bsky.social
Thank you to all who attended today's LoCITT-T webinar!

We received over 100 questions (plus the ~50 that came in earlier) 😅

We're writing up answers to all the q's & will send that w/ the recording & transcript within a week.

In the meantime, learn more at:
longcovid.scripps.edu/locitt-t/?ut...
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 5, 2025 at 9:08 PM
julialmv.bsky.social
It's such a joy to read about how LoCITT-T is perceived by the Long COVID community.

Multiple people, including @ezra.zone and @chromatowski.bsky.social, have articulated our approach and the reasons one might participate better than I have!

e.g. the thread below ⬇️
November 4, 2025 at 5:09 PM
julialmv.bsky.social
For more info and to enroll check out our website:
longcovid.scripps.edu/locitt-t/?ut...

And/or attend our webinar tomorrow (11/5); registration is required:
scrippsresearch.zoom.us/webinar/regi...
November 4, 2025 at 3:11 PM
julialmv.bsky.social
Reminder - the Long COVID Treatment Trial - Tirzepatide (LoCITT-T) is open in 49 US states (all but Hawaii), DC, & PR.

More info & eligibility survey here:
longcovid.scripps.edu/locitt-t/?ut...

We're hosting a webinar w/ Q&A on 11/5, register here:
scrippsresearch.zoom.us/webinar/regi...
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 3, 2025 at 4:37 PM
Reposted by Julia MV
devinsinger.bsky.social
I've had good results with tirazeptide for my long COVID so I'm excited about this study! (I'm not eligible because I'm already on it, but I wanted to spread the word.)
julialmv.bsky.social Julia MV @julialmv.bsky.social · 11d
The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is now open for enrollment for people with Long COVID in all states but Hawaii (due to concerns about maintaining temperature control in shipping), DC, and PR:
longcovid.scripps.edu/locitt-t/?ut...
October 31, 2025 at 6:24 PM
Reposted by Julia MV
atranscendedman.bsky.social
Researchers at Scripps Research have launched a fully remote clinical trial enrolling 1,000 US adults with long COVID to test whether the diabetes/obesity drug tirzepatide can relieve symptoms by reducing inflammation.

www.scripps.edu/news-and-eve...
Scripps Research scientists launch new digital clinical trial to test repurposed drug for long COVID symptom relief
www.scripps.edu
October 30, 2025 at 6:35 PM
julialmv.bsky.social
Forget Rumi, all the kids should be dressing as @edyong209.bsky.social
thesicktimes.org The Sick Times @thesicktimes.org · 11d
Happy Halloween! We have a some last-minute #LongCOVID themed costume ideas for you! 👻
ID 1: "Primary care doctor visit to diagnose Long COVID." A stock photo of a doctor looking smug surrounded by "normal lab results, no mask, anxiety diagnosis, shrug emoji pin, 'I don't even know what specialist I should send you to.'" ID 6: "The CDC." A person in a haunted house costume surrounded by "Delta Airlines pumpkin, a rotating horror of pandemic denying directors, jump scare COVID data dashboards, measles, mumps, rubella as a little treat." ID 5: "Group costume: which doctor will treat my Long COVID?" Seven Spider-Men in lab coats standing in a circle pointing at each other: PCP, cardiologist, OBGYN, neurologist, gastroenterologist, rheumatologist, dermatologist." ID 3: "Ed Yong." Science reporter Ed Yong surrounded by "blue button-up floral shirt, a literal Pulitzer Prize, binoculars 4 birding, enormous camera with a bird on it."
October 31, 2025 at 2:59 PM
julialmv.bsky.social
The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is now open for enrollment for people with Long COVID in all states but Hawaii (due to concerns about maintaining temperature control in shipping), DC, and PR:
longcovid.scripps.edu/locitt-t/?ut...
October 31, 2025 at 2:49 PM
Reposted by Julia MV
gregggonsalves.bsky.social
I am going to be that annoying friend. Get your #COVID & #flu shots. There is little downside to getting immunized and it will spare you from being out sick, having to go to the doctor's office, hospitalization and yes, death. Too many people aren't stepping up to get the shots. Do it this weekend.
October 31, 2025 at 10:55 AM
Reposted by Julia MV
erictopol.bsky.social
On our #LongCovid clinical trial launched today!
thesicktimes.org/2025/10/30/w... @julialmv.bsky.social @scripps.edu
We need more at-home clinical trials for Long COVID. Here’s how we designed the largest one yet. - The Sick Times
We are now recruiting for the Long COVID Treatment Trial-Tirzepatide (LoCITT-T), which participants can complete entirely from bed.
thesicktimes.org
October 30, 2025 at 11:05 PM
Reposted by Julia MV
chromatowski.bsky.social
Lots more background on this trial, including where the wonderful study team is coming from:

“When you are dealing with relentless, debilitating symptoms — each day matters. It can be the difference between experiencing life’s most meaningful events up close and seeing photos of them from afar.” 💔❤️
October 30, 2025 at 7:23 PM
Reposted by Julia MV
chromatowski.bsky.social
There are findings about GLP-1RA’s benefits in so many diseases, including MCAS ( www.amjmedsci.com/article/S000... ).

I’m so thrilled we’re getting such a robust trial to see what one can do in Long Covid.
October 30, 2025 at 7:08 PM
julialmv.bsky.social
2 things I forgot to mention in this lengthy thread:

1. We are hosting a webinar on 11/5 @ 2 eastern / 11 pacific where we will share more info & answer questions. Register here:
scrippsresearch.zoom.us/webinar/regi...

2. The clinical trials . gov link is:
clinicaltrials.gov/study/NCT071...
October 30, 2025 at 7:03 PM
Reposted by Julia MV
chromatowski.bsky.social
I was a (paid) test user for this trial and am thrilled w/the accommodations it makes to include people as severely ill as I am!

If you’re in the US and have Long Covid, check it out and share w/friends!

Also: if you don’t see your state yet, you can sign up to be alerted when yours is added!
julialmv.bsky.social Julia MV @julialmv.bsky.social · 11d
The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is officially open for enrollment for people with Long COVID in:
Alabama, Alaska, California, Florida, Illinois, Indiana, Michigan, Ohio, Pennsylvania, Texas, Utah
longcovid.scripps.edu/locitt-t/?ut...

1/16
LoCITT-T - Long COVID Treatment Trial
longcovid.scripps.edu
October 30, 2025 at 6:50 PM
julialmv.bsky.social
The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is officially open for enrollment for people with Long COVID in:
Alabama, Alaska, California, Florida, Illinois, Indiana, Michigan, Ohio, Pennsylvania, Texas, Utah
longcovid.scripps.edu/locitt-t/?ut...

1/16
LoCITT-T - Long COVID Treatment Trial
longcovid.scripps.edu
October 30, 2025 at 6:24 PM
julialmv.bsky.social
Confirming JD is an excellent strategist!
October 27, 2025 at 3:23 PM
Reposted by Julia MV
emilyesfraser.bsky.social
The exponential vs additive quality of post-exertional malaise is so important to understand. It makes the cost of exertion so much different & more dangerous in ME than in other chronic fatiguing illnesses
keristars.bsky.social keri @keristars.bsky.social · 18d
When fatigue is exhaustion but not coupled with PEM, the balance is different. My smom has MS, which has her constantly run down. Extra exertion doesn't have that exponential effect of PEM for her - it's simply additive. Leaving the house is tiring, but it doesn't cause days of extra weakness.

10/x
October 25, 2025 at 1:11 AM
Reposted by Julia MV
thesicktimes.org
💊 A clinical trial for Colchicine did not find the drug effective for Long COVID

🇮🇳 PLRC white paper: Long COVID disproportionately affects India’s productive-age population

🧐 Researchers critiqued controversial 2024 study on myalgic encephalomyelitis

#LongCOVID research updates: bit.ly/47nXfQS
A street vendor in a respirator cooks in front of an orange bus. The text reads, "Long COVID research updates. A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID. PLRC white paper: Long COVID disproportionately affects India’s productive-age population. Researchers critiqued controversial 2024 study on myalgic encephalomyelitis (ME)." A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks. The trial included outcome measures of a six-minute walk test, inflammatory markers, and participant surveys; none of them showed differences between the treatment and placebo groups. A white paper from the Patient-Led Research Collaborative assessed Long COVID in India by interviewing clinicians and people with the disease across the country in both urban and rural locations. “Clinicians emphasize that Long COVID disproportionately affects India’s productive-age population, pushing many into financial precarity or reliance on family support,” the study’s authors wrote. They also found that people may fear telling others that they have Long COVID due to stigma. The authors made numerous recommendations to improve clinical care, public health education, and research for the disease. Researchers recently critiqued the study design and conclusions of a controversial 2024 study on myalgic encephalomyelitis (ME), which asserted that the disease was a result of altered “effort preference” and deconditioning. They wrote in a response in Nature Communications, “this interpretation risks reinforcing skepticism about the serious biological nature of [ME] and its hallmark of post-exertional malaise (PEM), as well as its potential misclassification as a mental health condition.” The authors of the letter also critiqued the study’s small sample size, outcome measures, analyses, and more aspects of its design. We reported on the study’s errors and potential bias in 2024, and published commentary from a community member calling for its retraction.
October 23, 2025 at 2:58 PM
Reposted by Julia MV
thelancet.com
Antidepressants vary widely in their physical side effects, highlighting the need for personalised prescribing, says major meta-analysis.

Find out more: tinyurl.com/ycxzafd4
Research in context panel for Lancet paper "The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis". Copyright: 2025 The Author(s). Published by Elsevier Ltd. CC BY 4.0.
October 23, 2025 at 2:14 PM
julialmv.bsky.social
Sad & true
erictopol.bsky.social Eric Topol @erictopol.bsky.social · 20d
From a new @thelancet.com article today entitled "Health care in the USA: money has become the mission" www.thelancet.com/journals/lan...
October 22, 2025 at 2:35 AM
Reposted by Julia MV
erictopol.bsky.social
What did the largest trial of an early detection of cancer blood test show?
erictopol.substack.com/p/the-larges...
The Largest Study of a Multi-Cancer Early Detection Blood Test
Reviewing the new data and the "liquid biopsy" field
erictopol.substack.com
October 21, 2025 at 1:36 PM
julialmv.bsky.social
11% of the participants in this negative trial dropped out due to:
"the inability to visit the site for follow-up at 12 weeks"

& all these folks enrolled during a site visit

Yet another reason that accessible trials are crucial in Long COVID & other conditions

jamanetwork.com/journals/jam...

1/2
Effectiveness of Colchicine for the Treatment of Long COVID
This randomized clinical trial evaluates the superiority of colchicine over placebo among adults with long COVID in improving functional outcome at 52 weeks from baseline.
jamanetwork.com
October 21, 2025 at 2:33 PM